MX2021007967A - Inhibidores de síntesis de leucotrienos. - Google Patents
Inhibidores de síntesis de leucotrienos.Info
- Publication number
- MX2021007967A MX2021007967A MX2021007967A MX2021007967A MX2021007967A MX 2021007967 A MX2021007967 A MX 2021007967A MX 2021007967 A MX2021007967 A MX 2021007967A MX 2021007967 A MX2021007967 A MX 2021007967A MX 2021007967 A MX2021007967 A MX 2021007967A
- Authority
- MX
- Mexico
- Prior art keywords
- leukotriene synthesis
- synthesis inhibitors
- compounds
- pharmaceutical compositions
- leukotriene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
- C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791641P | 2019-01-11 | 2019-01-11 | |
| PCT/US2020/013217 WO2020146822A1 (en) | 2019-01-11 | 2020-01-10 | Leukotriene synthesis inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007967A true MX2021007967A (es) | 2021-09-21 |
Family
ID=71520894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007967A MX2021007967A (es) | 2019-01-11 | 2020-01-10 | Inhibidores de síntesis de leucotrienos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11976052B2 (https=) |
| EP (1) | EP3908278A4 (https=) |
| JP (2) | JP7680955B2 (https=) |
| KR (2) | KR102920650B1 (https=) |
| CN (1) | CN113784713A (https=) |
| AU (2) | AU2020206036A1 (https=) |
| BR (1) | BR112021013637A2 (https=) |
| CA (1) | CA3126021A1 (https=) |
| MX (1) | MX2021007967A (https=) |
| SG (1) | SG11202107080VA (https=) |
| WO (1) | WO2020146822A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3908278A4 (en) * | 2019-01-11 | 2022-09-28 | Naegis Pharmaceuticals Inc. | INHIBITORS OF LEUKOTRIEN SYNTHESIS |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661499A (en) | 1985-06-18 | 1987-04-28 | Merck Frosst Canada, Inc. | 2-[(substituted)-phenoxymethyl]quinolines |
| GB9122590D0 (en) * | 1991-10-24 | 1991-12-04 | Lilly Industries Ltd | Pharmaceutical compounds |
| WO1994006802A1 (fr) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Compose de thienodiazepine et son utilisation medicinale |
| ES2062943B1 (es) | 1993-03-23 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de la (2-metil-3-piridil) cianometilpiperazinas. |
| US5486612A (en) * | 1993-12-14 | 1996-01-23 | Eli Lilly And Company | N-benzyl dihydroindole LTD4 antagonists |
| FR2734265B1 (fr) | 1995-05-17 | 1997-06-13 | Adir | Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant |
| US5783586A (en) | 1996-10-01 | 1998-07-21 | Abbott Laboratories | Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis |
| EP0968179B1 (en) * | 1997-02-25 | 2002-09-25 | Syngenta Participations AG | N-sulphonyl and n-sulphinyl amino acid amides as microbiocides |
| ATE233104T1 (de) * | 1997-09-18 | 2003-03-15 | Janssen Pharmaceutica Nv | Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| PL359619A1 (en) | 2000-06-23 | 2004-08-23 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| JP2004513935A (ja) | 2000-11-17 | 2004-05-13 | ノボ ノルディスク アクティーゼルスカブ | グルカゴンアンタゴニスト／逆アゴニスト |
| US20030203946A1 (en) | 2000-11-17 | 2003-10-30 | Carsten Behrens | Glucagon antagonists/inverse agonists |
| US20050070506A1 (en) * | 2002-01-18 | 2005-03-31 | Doherty George A. | Selective s1p1/edg1 receptor agonists |
| WO2004063147A1 (en) | 2003-01-10 | 2004-07-29 | Novo Nordisk A/S | Salts and solvates of glucagon antagonists |
| US7329682B2 (en) | 2003-04-03 | 2008-02-12 | Ewha University-Industry Collaboration Foundation | Method for inhibiting 5-lipoxygenase using a benzoxazole derivative |
| CN1856490A (zh) * | 2003-07-28 | 2006-11-01 | 詹森药业有限公司 | 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 |
| UA86283C2 (uk) | 2005-01-07 | 2009-04-10 | Пфайзер Продактс Инк. | Гетероароматичні сполуки хіноліну і їх застосування як інгібіторів pde10 |
| US20060223792A1 (en) * | 2005-03-31 | 2006-10-05 | Butler Christopher R | Phenyl and pyridyl LTA4H modulators |
| PE20070335A1 (es) | 2005-08-30 | 2007-04-21 | Novartis Ag | Benzimidazoles sustituidos y metodos para su preparacion |
| US7939528B2 (en) * | 2005-10-13 | 2011-05-10 | Glaxosmithkline Llc | Heterocycle compounds |
| DE102006021878A1 (de) | 2006-05-11 | 2007-11-15 | Sanofi-Aventis | Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
| TW200906396A (en) * | 2007-02-14 | 2009-02-16 | Janssen Pharmaceutica Nv | LTA4H modulators and uses thereof |
| AU2008256922B2 (en) | 2007-05-23 | 2011-07-28 | Novartis Ag | Raf inhibitors for the treatment of thyroid cancer |
| AR069126A1 (es) * | 2007-10-31 | 2009-12-30 | Janssen Pharmaceutica Nv | Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa |
| US9446995B2 (en) | 2012-05-21 | 2016-09-20 | Illinois Institute Of Technology | Synthesis of therapeutic and diagnostic drugs centered on regioselective and stereoselective ring opening of aziridinium ions |
| SI2336125T1 (sl) * | 2008-04-11 | 2013-04-30 | Janssen Pharmaceutica N.V. | Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze |
| WO2009132202A2 (en) | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| MX2010013683A (es) | 2008-06-13 | 2011-04-26 | Novartis Ag | Bencimidazoles sustituidos para neurofibromatosis. |
| TW201010977A (en) | 2008-08-12 | 2010-03-16 | Takeda Pharmaceutical | Amide compound |
| WO2010059163A1 (en) | 2008-11-21 | 2010-05-27 | Hassan Hamza | Adjustable vacuum relief safety valve system for swimming pools and spas |
| PT2391366E (pt) | 2009-01-29 | 2013-02-05 | Novartis Ag | Benzimidazoles substituídos para o tratamento de astrocitomas |
| WO2014077401A1 (ja) | 2012-11-19 | 2014-05-22 | 武田薬品工業株式会社 | 含窒素複素環化合物 |
| WO2014129796A1 (en) | 2013-02-20 | 2014-08-28 | Lg Life Sciences Ltd. | Sphingosine-1-phosphate receptor agonists, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent |
| CN104045552B (zh) | 2013-03-13 | 2019-06-11 | 江苏先声药业有限公司 | 作为神经保护剂的药用化合物 |
| US20160101106A1 (en) | 2013-05-07 | 2016-04-14 | Inhibikase Therapeutics, Inc. | Methods for treating hcv infection |
| SG11201509351UA (en) | 2013-06-10 | 2015-12-30 | Bayer Pharma AG | Novel compounds for the treatment of cancer |
| EP3102569A1 (en) | 2014-02-06 | 2016-12-14 | AbbVie Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| SG11201609050UA (en) * | 2014-05-30 | 2016-12-29 | Pfizer | Carbonitrile derivatives as selective androgen receptor modulators |
| EP3328860B2 (en) | 2015-07-28 | 2022-11-02 | UDC Ireland Limited | Process for the preparation of benzimidazo[1,2-a]benzimidazoles |
| BR112018003711A2 (pt) * | 2015-08-26 | 2018-09-25 | Texas A & M Univ Sys | método para sensibilização de um parasita a um fármaco e método para prevenir infecção sintomática de um paciente por um parasita ou tratar infecção de um paciente por um parasita com um fármaco |
| AR111495A1 (es) | 2017-05-01 | 2019-07-17 | Theravance Biopharma R&D Ip Llc | Compuestos de imidazo-piperidina fusionada como inhibidores de jak |
| CN107383014B (zh) | 2017-06-21 | 2019-04-30 | 南方医科大学 | 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用 |
| EP3908278A4 (en) * | 2019-01-11 | 2022-09-28 | Naegis Pharmaceuticals Inc. | INHIBITORS OF LEUKOTRIEN SYNTHESIS |
-
2020
- 2020-01-10 EP EP20738780.4A patent/EP3908278A4/en active Pending
- 2020-01-10 AU AU2020206036A patent/AU2020206036A1/en not_active Abandoned
- 2020-01-10 KR KR1020217025364A patent/KR102920650B1/ko active Active
- 2020-01-10 BR BR112021013637-1A patent/BR112021013637A2/pt not_active Application Discontinuation
- 2020-01-10 CA CA3126021A patent/CA3126021A1/en active Pending
- 2020-01-10 KR KR1020267002672A patent/KR20260018201A/ko active Pending
- 2020-01-10 JP JP2021538484A patent/JP7680955B2/ja active Active
- 2020-01-10 US US17/420,885 patent/US11976052B2/en active Active
- 2020-01-10 WO PCT/US2020/013217 patent/WO2020146822A1/en not_active Ceased
- 2020-01-10 MX MX2021007967A patent/MX2021007967A/es unknown
- 2020-01-10 CN CN202080018627.3A patent/CN113784713A/zh active Pending
- 2020-01-10 SG SG11202107080VA patent/SG11202107080VA/en unknown
-
2024
- 2024-02-28 US US18/590,523 patent/US20250011293A1/en active Pending
- 2024-12-25 JP JP2024228232A patent/JP2025060830A/ja active Pending
-
2025
- 2025-10-17 AU AU2025252635A patent/AU2025252635A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3908278A4 (en) | 2022-09-28 |
| AU2025252635A1 (en) | 2025-11-06 |
| JP2022517316A (ja) | 2022-03-08 |
| US11976052B2 (en) | 2024-05-07 |
| CA3126021A1 (en) | 2020-07-16 |
| KR20210123321A (ko) | 2021-10-13 |
| CN113784713A (zh) | 2021-12-10 |
| BR112021013637A2 (pt) | 2021-09-14 |
| KR20260018201A (ko) | 2026-02-06 |
| JP7680955B2 (ja) | 2025-05-21 |
| US20220064132A1 (en) | 2022-03-03 |
| WO2020146822A1 (en) | 2020-07-16 |
| JP2025060830A (ja) | 2025-04-10 |
| US20250011293A1 (en) | 2025-01-09 |
| SG11202107080VA (en) | 2021-07-29 |
| KR102920650B1 (ko) | 2026-01-29 |
| EP3908278A1 (en) | 2021-11-17 |
| AU2020206036A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202007007B (en) | Mcl-1 inhibitors | |
| PH12020551244A1 (en) | Pd-1/pd-l1 inhibitors | |
| PH12021500004A1 (en) | Pd-1/pd-l1 inhibitors | |
| MX2024009727A (es) | Terapias de combinacion. | |
| MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| PH12022550892A1 (en) | Bicyclic heterocycles as fgfr inhibitors | |
| MX2020013649A (es) | Composiciones y metodos para inhibir la actividad de la arginasa. | |
| EP4438117A3 (en) | Tyk2 inhibitors and uses thereof | |
| MX2018005600A (es) | Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello. | |
| EP3848370A3 (en) | Tyk2 inhibitors and uses thereof | |
| PH12020552214A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| ZA202204941B (en) | Cd73 inhibitors | |
| PH12023552079A1 (en) | Cdk2 inhibitors and methods of using the same | |
| SA519410093B1 (ar) | مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز | |
| MX2020006365A (es) | Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14). | |
| AU2020258568A8 (en) | CD73 inhibitors | |
| MX2021003643A (es) | Derivados de terpenoides y usos de los mismos. | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| AU2020378127A8 (en) | Compounds as CD73 inhibitors | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| MX2021007967A (es) | Inhibidores de síntesis de leucotrienos. | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| WO2020106751A8 (en) | Inhibitors of gli1 as therapeutic agents | |
| WO2020136298A3 (es) | Inhibidores de la caspasa 1 para uso en el tratamiento de la anemia | |
| MX2020010156A (es) | Inhibidores de la secrecion de proteina cdp. |